Pharmacokinetic-pharmacodynamic relationships for benzodiazepines

Clinical Pharmacokinetics

Volumn 30, Issue 1, 1996, Pages 52-76

  Laurijssens, Bart E ^a   Greenblatt, David J ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADINAZOLAM; ALFENTANIL; ALPRAZOLAM; ANTIFUNGAL AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CALCIUM ANTAGONIST; DIAZEPAM; FLUNITRAZEPAM; KETOCONAZOLE; LORAZEPAM; MACROLIDE; MIDAZOLAM; NITRAZEPAM; PROBENECID; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRIAZOLAM;

AGE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOOD; NONHUMAN; ORAL DRUG ADMINISTRATION; PANIC; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REVIEW; SEDATION;

EID: 0030069622     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630010-00004     Document Type: Review

References (111)

1. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992; 44: 151-347
2. Hollister LE, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 13 (Dec Suppl.): 1S-169S
3. Greenblatt DJ, Friedman HL, Shader RI. Correlating pharmacokinetics and pharmacodynamics of benzodiazepines: problems and assumptions. In: Dahl SG, Gram LF, Paul SM, et al., editors. Clinical pharmacology in psychiatry. Selectivity in psychotropic drug action - promises or problems. Berlin/Heidelberg: Springer-Verlag, 1987: 62-71
4. Grevel J. Kinetic-effect models and their applications. Pharm Res 1987; 4: 86-91
5. Greenblatt DJ, Harmatz JS. Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol 1993; 13: 231-4
6. Campbell DB. The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology 1990; 100: 433-50
7. Dingemanse J, Danhof M, Breimer DD. Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther 1988; 38: 1-52
8. Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992; 23: 191-215
9. Greenblatt DJ. Principles of pharmacokinetics and pharmacodynamics. In: Nemeroff CB, Schatzberg AF, editors. The American Psychiatric Press Textbook of Psychopharmacology. Washington (DC): American Psychiatric Press, 1995: 125-36
10. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (Part II). Clin Pharmacokinet 1991; 21: 262-73
11. Hommer DW, Matsuo VM, Wolkowitz O, et al. Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 1986; 43: 542-51
12. Roy-Byrne PP, Lewis N, Villacres E, et al. Suppression of norepinephrine appearance rate in plasma by diazepam in humans. Life Sci 1988; 43: 1615-23
13. Breimer LTM, Burm AGL, Danhof M, et al. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Clin Pharmacokinet 1991; 20: 497-508
14. Greenblatt DI, Harmatz JS, Gouthro TA, et al. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994; 56: 100-11
15. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691-8
16. Kaiser L. Adjusting for baseline: change or percentage change. Stat Med 1989; 8: 1183-90
17. Wainer H. Adjusting for differential base rates: Lord's paradox again. Psychol Bull 1991; 109: 147-51
18. Crevoisier C, Ziegler WH, Eckert M, et al. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 1983; 16: 51S-61S
19. Ellinwood EH, Nikaido AM, Gupta SK, et al. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. J Psychopharmacol 1993; 7: 24-32
20. Koopmans R, Dingemanse J, Danhof M, et al. The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. Clin Pharmacol Ther 1991; 50: 16-24
21. Kroboth PD, Bertz RJ, Smith RB. Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constant. J Pharmacol Exp Ther 1993; 264: 1047-55
22. Holford NHG, Sheiner LB. Kinetics of pharmacological response. Pharmacol Ther 1982; 16: 143-66
23. Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm 1981; 9: 367-88
24. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71
25. Fusea IE, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984; 35: 733-41
26. Veng-Pedersen P, Mandema JW, Danhof M. A system approach to pharmacodynamics, III: an algorithm and computer program 'COLAPS' for pharmacodynamic modelling. J Pharm Sci 1991; 80: 488-95
27. Verotta D, Beal SL, Sheiner LB. Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol 1984; 256: R1005-10
28. Ekblom M, Hammarlund-Udenaes M, Paalzow L. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. J Pharmacol Exp Ther 1993; 266: 244-52
29. Porchet HC, Benowitz, NL, Sheiner LB. Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 1938; 244: 231-6
30. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 19: 521-36
31. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406-19
32. Levy G. Mechanism-basad pharmacodynamic modeling. Clin Pharmacol Ther 1994; 56: 356-8
33. Smith RB, Kroboth PD, Varner PD. Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 1987; 27: 971-9
34. Sunzel M, Paalzow L, Berggren L, et al. Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam. Br J Clin Pharmacol 1988; 25: 561-9
35. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989; 45: 356-65
36. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Kinetic and dynamic study of intravenous lorazepam: comparisom with intravenous drazepam. J Pharmacol Exp Ther 1989; 250: 134-40
37. Breimer LTM, Hennis PJ, Burm AGL, et al. Quantification of the EEG effect of midazulam by aperiodic analysis in volunteers: pharmacokinetic/pharmacodynamic modelling. Clin Pharmacokinet 1990; 18: 245-53
38. Bührer M, Maitre PO, Crevoisier C, et al. Electroencephalographic effects of benzodiazepines. II: Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Clin Pharmacol Ther 1990; 48: 555-67
39. Fleishaker JC, Smith TC, Friedman H. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in healthy volunteers. Eur J Clin Pharmacol 1992; 42: 287-94
40. Derry CL, Kroboth PD, Pittenger AL, et al. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J Clin Psychopharmacol 1995; 15: 197-205
41. Mould DR, DeFeo TM, Reele S, et al. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Clin Pharmacol Ther 1995; 35: 35-43
42. Persson MP, Nilsson A, Hartvig P. Relation of sedation and amnesia to plasma concentrations of midazolam in surgical patients. Clin Pharmacol Ther 1988; 43: 324-31
43. Osman OT, DeVane CL, Greenblatt DJ, et al. Pharmacokinetic and dynamic correlates of intravenus alprazolam challenge. Clin Pharmacol Ther 1991; 50: 656-62
44. Short TG, Young KK, Tan P, et al. Midazolam and flumazenil pharmacokinetics and pharmacodynamics following simultaneous administration to human volunteers. Acta Anaesthesiol Scand 1994; 38: 350-6
45. Fink M, Irwin P, Weinfeld RE, et al. Blood levels and electroencephalographic effects of diazepam and bromazepam. Clin Pharmacol Ther 1976; 20: 184-91
46. MacLeod SM, Giles HG, Patzalek G, et al. Diazepam actions and plasma concentrations following ethanol ingestion. Eur J Clin Pharmacol 1977; 11: 345-9
47. Bittencourt PRM, Wade P, Smith AT, et al. The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration. Br J Clin Pharmacol 1981; 12: 523-33
48. Ellinwood EH, Linnoila M, Easler MF, et al. Profile of acute tolerance to three sedative anxiolytics. Psychopharmacology 1983; 79: 137-41
49. Baktir G, Fisch HU, Huguenin P, et al. Triazolam concentration-effect relationships in healthy subjects. Clin Pharmacol Ther 1983; 34: 195-201
50. Ellinwood EH, Easler ME, Linnoila M, et al. Effects of oral contraceptives on diazepam-induced psychomotor impairment. Clin Pharmacol Ther 1984; 35: 360-6
51. O'Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984; 18: 121S-129S
52. Stevens LA, Pidgen AW, Bevan CD, et al. Correlation of the clinical pharmacodynamics of loprazolam with serum concentration. Xenobiotica 1985; 15: 623-31
53. Ellinwood EH, Heatherly DG, Nikaido AM, et al. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 1985; 86: 392-9
54. Ellinwood EH, Nikaido AM, Heatherly DG, et al. Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms. Psychopharmacology 1987; 91: 168-74
55. Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 1987; 93: 105-12
56. Koopmans R, Dingemanse J, Danhof M, et al. Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system. Clin Pharmacol Ther 1988; 44: 14-22
57. Fleishaker JC, Phillips JP. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology 1989; 99: 34-9
58. Greenblatt DJ, Harmatz JS, Engelhardt N, et al. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Arch Gen Psychiatry 1989; 46: 326-32
59. Gupta SK, Ellinwood EH, Nikaido AM, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines, II: Triazolam. Pharm Res 1990; 7: 570-6
60. Gupta SK, Ellinwood EH, Nikaido AM, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. 1: Lorazepam. J Pharmacokinet Biopharm 1990; 18: 89-102
61. Kroboth PD, McAuley JW, Smith RB. Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing. Psychopharmacology 1990; 100: 477-84
62. Fleishaker JC, Smith TC, Friedman H, et al. N-desmethyl-adinazolam pharmacokinetics and behavioral effects following administration of 10-50 mg oral doses in healthy volunteers. Psychopharmacology 1991; 105: 181-5
63. Grahnén S, Wennerlund B, Dahlström B, et al. Inter-and intra-individual variability in the concentration-effect (sedation) relationship of flunitrazepam. Br J Clin Pharmacol 1991; 31: 89-92
64. Schmith VD, Piraino B, Smith RB, et al. Alprazolam in end-stage renal disease. II: Pharmacodynamics. Clin Pharmacol Ther 1992; 51: 533-40
65. Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992; 52: 139-50
66. van Steveninck AL, Schoemaker HC, Pieters MSM, et al. A comparison of the sensitivities of adaptive tracking, eye movement analysis, and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 1991; 50: 172-80
67. van Steveninck AL, Verver S, Schoemaker HC, et al. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther 1992; 52: 402-8
68. Osborne GA, Badcock NR, McGrath PM, et al. The relationship between the concentration of temazepam in cerebrospinal fluid and sedation in man. Anaesthesia 1992; 47: 303-6
69. Greenblatt DJ, Scavone JM, Harmatz JS, et al. Cognitive effects of β-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propanolol, atenolol, lorazepam, and placebo. Clin Pharmacol Ther 1993; 53: 577-84
70. Golden PL, Warner PE, Fleishaker JC, et al. Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans. Clin Pharmacol Ther 1994; 56: 133-41
71. McAuley JW, Reynolds IJ, Kroboth FJ, et al. Orally administered progesterone enhances sensitivity to triazolam in postmenopausal woman. J Clin Psychopharmacol 1995; 15: 3-11
72. Moffat AC, Osborne GA, Badcock NR, et al. The relationship between clinical effect and concentrations of temazepam in plasma and cerebrospinal fluid. Anaesthesia 1995; 50: 3-8
73. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther. In press, 1995
74. Miller LG, Greenblatt DJ, Paul SM, et al. Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther 1987; 240: 516-22
75. Greenblatt DJ, Sethy VH. Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psychopharmacology 1990; 102: 373-8
76. Mandema JW, Sansom LN, Dios-Vieitez MC, et al. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 1991; 257: 472-8
77. Mandema JW, Kuck MT, Danhof M. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br J Pharmacol 1992; 105: 164-70
78. Mandema JW, Tukker E, Danhof M. In vivo characterization of the pharmacodynamic interaction of benzodiazepine agonist and antagonist: midazolam and flumazenil. J Pharmacol Exp Ther 1992; 260: 36-44
79. Mandema JW, Kuck MT, Danhof M. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. J Pharmacol Exp Ther 1992; 261: 56-61
80. Dingemanse J, Sollie FAE, Breimer DD, et al. Pharmacokinetic modelling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazole threshold concentration as pharmacodynamic measure. J Pharmacokinet Biopharm 1988; 16: 203-28
81. Hollander-Jansen M, Dingemanse J, Langemeijer MWE, et al. Relation between receptor occupancy and anticonvulsant effect of flunitrazepam in rats. Pharm Res 1989; 6: 585-91
82. Dingemanse J, Voskuyl RA, Langemeijer MWE, et al. Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. Br J Pharmacol 1990; 99: 53-8
83. Hoogerkamp A, Vis PW, Danhof M, et al. Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat. J Pharmacol Exp Ther 1994; 269: 521-8
84. Hall RI, Szlam F, Hug CC. Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. J Pharmacokinet Biopharm 1988; 16: 251-62
85. Court MH, Dodman NH, Greenblatt DJ, et al. Effect of midazolam infusion and flumazenil administration on epinephrine arrhythmogenicity in dogs anesthesized with halothane. Anesthesiology 1993; 78: 155-62
86. Bond AJ, Hailey DM, Lader MH. Plasma concentrations of benzodiazepines. Br J Clin Pharmacol 1977; 4: 51-6
87. Dasberg HH, van der Kleijn E, Guelen PJR, et al. Plasma concentrations of diazepam and of its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clin Pharmacol Ther 1973; 15: 473-83
88. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50: 715-22
89. Wincor MZ, Munjack DJ, Palmer R. Alprazolam levels and response in panic disorder: preliminary results. J Clin Psychopharmacol 1991; 11: 48-51
90. Ciraulo DA, Barnhill JG, Boxenbaum HG, et al. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. J Clin Pharmacol 1986; 26: 292-8
91. Ciraulo DA, Antal EJ, Smith RB, et al. The relation of alprazolam dose to steady-state plasma concentrations. J Clin Psychopharmacol 1990; 10: 27-32
92. Lesser IM, Lydiard B, Antal E, et al. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992; 149: 1556-62
93. Fleishaker JC, Phillips JP, Eller MG, et al. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation. J Clin Pharmacol 1989; 29: 543-9
94. Smith RB, Kroboth PD, Vanderlugt JT, et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 1984; 84: 452-6
95. Kroboth PD, Smith RB. Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 1988; 43: 270-7
96. Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715-28
97. Mandema JW, Tukker E, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 1991; 102: 663-8
98. Kroboth PD, McAuley JW, Derry CL. Time-dependent sensitization to triazolam? An observation in three studies. J Clin Psychopharmacol 1995; 15: 192-6
99. Stijnen AM. The influence of ageing on the pharmacodynamics of sedative anticonvulsant drugs in rats [Ph.D. thesis). Leiden: University of Leiden, 1991
100. Scavone JM, Friedman H, Greenblatt DJ, et al. Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. Arztneim Forsch 1987; 37: 2-6
101. Barnhill JG, Greenblatt DJ, Miller LG, et al. Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J Pharmacol Exp Ther 1990; 253: 1153-61
102. Hovinga S, Stijnen AM, Langemeijer MWE, et al. Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. Br J Pharmacol 1992; 107: 171-7
103. Jacobs JR, Reves JG, White WD, et al. Aging increases pharmacodynamic sensitivity to the hypnotic effects of midazolam. Anesthesiol Analg 1995; 80: 143-8
104. Roy-Byrne PP, Lewis N, Villacres E, et al. Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biol Psychiatry 1989; 26: 744-8
105. Roy-Byrne PP, Cowley DS, Greenblatt DJ, et al. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47: 534-8
106. Ochs HR, Greenblatt DJ, Eckardt B, et al. Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther 1983; 33: 471-6
107. Robin DW, Lee M, Hasan SS, et al. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 630-7
108. Bakti G, Fisch HU, Karlaganis G, et al. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 1987; 7: 629-38
109. Schmith VD, Piraino B, Smith RB, et al. Alprazolam in end-stage renal disease. I: Pharmacokinetics. J Clin Pharmacol 1991; 31: 571-9
110. Hoyo-Vadillo C, Mandema JW, Danhof M. Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. Life Sci 1995; 57: 325-33
111. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93-141